

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the claims:

Claim 1-3 (Canceled).

Claim 4 (Currently Amended) ~~[[The]] A composition comprising of claim 1 wherein the two or more recombinant polypeptides comprise~~ five meningococcal antigens: (1) a 'NadA' protein; (2) a 'NMB1870[[741]]' protein; (3) a 'NMB2091[[936]]' protein; (4) a 'NMB1030[[953]]' protein; and (5) a 'NMB2132[[287]]' protein, wherein the composition after administration to a subject is able to induce an antibody response in that subject, wherein the antibody response is bactericidal against two or more of hypervirulent lineages A4, ET-5 and lineage 3 of N.meningitidis serogroup B.

Claim 5 (Currently Amended) The composition of claim 4, wherein the NadA protein has 85% or more sequence identity to SEQ ID 2.

Claim 6 (Original) The composition of claim 5, wherein the NadA protein comprises SEQ ID 2.

Claim 7 (Currently Amended) The composition of claim 4, wherein the NMB1870[[741]] protein has 85% or more sequence identity to SEQ ID 3.

Claim 8 (Currently Amended) The composition of claim 7, wherein the NMB1870[[741]] protein comprises SEQ ID 3.

Claim 9 (Currently Amended) The composition of claim 4, wherein the NMB2091[[936]] protein has 85% or more sequence identity to SEQ ID 4.

Claim 10 (Currently Amended) The composition of claim 9, wherein the NMB2091[[936]] protein comprises SEQ ID 4.

Claim 11 (Currently Amended) The composition of claims 4, wherein the NMB1030[[953]] protein has 85% or more sequence identity to SEQ ID 5.

Claim 12 (Currently Amended) The composition of claim 11, wherein NMB1030[[953]] protein comprises SEQ ID 5.

Claim 13 (Currently Amended) The composition of claim 4, wherein the NMB2132[[287]] protein has 85% or more sequence identity to SEQ ID 6.

Claim 14 (Currently Amended) The composition of claim 13, wherein the NMB2132[[287]] protein comprises SEQ ID 6.

Claim 15 (Previously Amended) The composition of claim 4, wherein at least two of the antigens (1) to (5) are expressed as a single polypeptide chain.

Claim 16 (Withdrawn-Currently Amended) The composition of claim 4 [[1]], wherein the two recombinant polypeptides are expressed as a single polypeptide chain and are selected from the group of antigens consisting of: a 'NadA' protein & a 'NMB1870[[741]]' protein; the 'NadA' protein & a 'NMB2091[[936]]' protein; the 'NadA' protein & a 'NMB1030[[953]]' protein; the 'NadA' protein & a 'NMB2132[[287]]' protein; the 'NMB1870[[741]]' protein & the 'NMB2091[[936]]' protein; the 'NMB1870[[741]]' protein & the 'NMB1030[[953]]' protein; the 'NMB1870[[741]]' protein & the 'NMB2132[[287]]' protein; the 'NMB2091[[936]]' protein & the 'NMB1030[[953]]' protein; the 'NMB2091[[936]]' protein & the 'NMB2132[[287]]' protein; the 'NMB1030[[953]]' protein & the 'NMB2132[[287]]' protein.

Claim 17 (Withdrawn-Currently Amended) The composition of claims 15 or 16, wherein the single polypeptide chain comprises a polypeptide of formula $\text{NH}_2\text{-A-X}_1\text{-L-X}_2\text{-B-COOH}$, wherein: X_1 is an amino acid sequence of one of the five antigens selected from the group consisting of the 'NadA' protein, the 'NMB1870[[741]]' protein; the 'NMB2091[[936]]' protein; the 'NMB1030[[953]]' protein; and the 'NMB2132[[287]]' protein; X_2 is an amino acid sequence of one of the five antigens selected from the group consisting of the 'NadA' protein, the 'NMB1870[[741]]' protein; the 'NMB2091[[936]]' protein; the 'NMB1030[[953]]' protein; and the 'NMB2132[[287]]' protein provided that X_1 is not the same as X_2 ; L is an optional linker amino acid sequence; A is an optional N-terminal amino acid sequence; and B is an optional C-terminal amino acid sequence.

Claim 18 (Withdrawn-Currently Amended) The composition of claim 17, wherein X_1 is the NMB2091[[936]] protein and X_2 is the NMB1870[[741]] protein.

Claim 19 (Withdrawn-Currently Amended) The composition of claim 17, wherein X_1 is the NMB2132[[287]] protein and X_2 is the NMB1030[[953]] protein.

Claims 20-21 (Canceled).

Claim 22 (Withdrawn) The composition of claim 4, further comprising saccharide antigens from meningococcus serogroups Y, W135, C and (optionally) A.

Claim 23 (Withdrawn) The composition of claim 4, further comprising a saccharide antigen from *Haemophilus influenzae* type B.

Claim 24 (Withdrawn) The composition of claim 22 or claim 23, wherein the saccharide antigen is conjugated to a carrier selected from: diphtheria toxoid, tetanus toxoid, CRM₁₉₇ or *H.influenzae* protein D.

Claim 25 (Withdrawn) The composition of claim 4, further comprising an antigen from *Streptococcus pneumoniae*.

Claim 26 (Currently Amended) The composition of claims ~~1-4~~ 4 further comprising a pharmaceutically acceptable carrier.

Claim 27 (Canceled).

Claim 28 (Withdrawn-Currently Amended) A method for raising an antibody response in a mammal, comprising the step of administering an effective amount of a composition according to any one of claims [[1.]] 4, 15, or 16.

Claims 29-31 (Canceled).